ARTICLE | Finance
Play it again
Why Atlas is backing oncolytic virus company Replimune
September 28, 2015 7:00 AM UTC
Atlas Venture's decision to seek out an oncolytic virus investment coincided with the ex-management of BioVex Inc. looking to reunite to develop a next-generation product. The result was last week's $30 million series A round for Replimune Ltd.
Replimune's co-founders include Executive Chairman Philip Astley-Sparke and CEO Robert Coffin. Coffin founded BioVex and was its CTO. Astley-Sparke served as chairman, president and CEO. BioVex's lead asset, talimogene laherparepvec (T-Vec), has an Oct. 27 PDUFA date to treat regionally or distantly metastatic melanoma. ...